Decreased plasma levels of select very long chain ceramide species Are associated with the development of nephropathy in type 1 diabetes

Metabolism: Clinical and Experimental

Volumn 63, Issue 10, 2014, Pages 1287-1295

  Klein, Richard L ^a,b   Hammad, Samar M ^a,d   Baker, Nathaniel L ^a   Hunt, Kelly J ^a,b   Al Gadban, Mohammed M ^a   Cleary, Patricia A ^c   Virella, Gabriel ^a   Lopes Virella, Maria F ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Albuminuria; Macroalbuminuria; Microalbuminuria; Sphingolipids; Sphingosine

Indexed keywords

ALBUMIN; CERAMIDE; HEMOGLOBIN A1C; TRIACYLGLYCEROL; SPHINGOLIPID; SPHINGOSINE;

ADOLESCENT; ADULT; ARTICLE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; ALBUMINURIA; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS;

ALBUMINURIA; MACROALBUMINURIA; MICROALBUMINURIA; SPHINGOLIPIDS; SPHINGOSINE;

ADULT; ALBUMINURIA; CERAMIDES; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPHINGOLIPIDS;

EID: 84908248738     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.07.001     Document Type: Article

References (37)

1. F. Locatelli, B. Canaud, and K.U. Eckardt The importance of diabetic nephropathy in current nephrological practice Nephrol Dial Transplant 18 2003 1716 1725
2. National Kidney Foundation KDOQI Clinical practice guidelines for diabetes and CKD: 2012 update Am J Kidney Dis 60 2012 850 886
3. G.C. Viberti, R.D. Hill, and R.J. Jarrett Microalbuminuria as predictor of clinical nephropathy in insulin-dependent diabetes mellitus Lancet 1 1982 1430 1432
4. C.E. Mogensen Microalbuminuria as a predictor of clinical diabetic nephropathy Kidney Int 31 1987 673 689
5. H.C. Gerstein, J.F. Mann, and Q. Yi Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals J Am Med Assoc 286 2001 421 426
6. T.E. Fox, and M. Kester Therapeutic strategies for diabetes and complications: a role for sphingolipids Adv Exp Med Biol 688 2010 206 216
7. S.M. Hammad, J.S. Pierce, and F. Soodavar Blood sphingolipidomics in healthy humans: impact of sample collection methodology J Lipid Res 51 2010 3074 3087
8. M.H. Lee, S.M. Hammad, and A.J. Semler HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate J Lipid Res 51 2010 2619 2628
9. S.M. Hammad, M.M. Al Gadban, and A.J. Semler Sphingosine 1-phosphate distribution in plasma: associations with atypical lipoprotein profiles J Lipids 2012 2012 180705
10. F. Okajima Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 1582 2002 132 137
11. P. Wiesner, K. Leidl, and A. Boettcher Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry J Lipid Res 50 2009 574 585
12. N. Murata, K. Sato, and J. Kon Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions Biochem J 352 Pt 3 2000 809 815
13. V.P. Mäkinen, T. Tynkkynen, and P. Soininen Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study) Metabolomics 8 2012 369 375
14. T.E. Fox, M.C. Bewley, and K.A. Unrath Circulating sphingolipid biomarkers in models of type 1 diabetes J Lipid Res 52 2011 509 517
15. J.A. Chavez, and S.A. Summers A ceramide-centric view of insulin resistance Cell Metab 15 2012 585 594
16. B.T. Bikman, and S.A. Summers Ceramides as modulators of cellular and whole-body metabolism J Clin Invest 121 2011 4222 4230
17. S. Galadari, A. Rahman, and S. Pallichankandy Role of ceramide in diabetes mellitus: evidence and mechanisms Lipids Health Dis 12 2013 98 113
18. S.A. Summers Sphingolipids and insulin resistance: the five Ws Curr Opin Lipidol 21 2010 128 135
19. W.L. Holland, and S.A. Summers Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism Endocr Rev 29 2008 381 402
20. J.M. Haus, S.R. Kashyap, and T. Kasumov Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance Diabetes 58 2009 337 343
21. M. Gorska, A. Dobrzyn, and M. Baranowski Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes Med Sci Monit 11 2005 CR35 CR38
22. The Diabetes Control and Complications Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
23. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort Diabetes Care 22 1999 99 111
24. S. Sonnino, and A. Prinetti Membrane domains and the "Lipid Raft" concept Curr Med Chem 20 2013 4 21
25. Y. Zhang, X. Li, and K.A. Becker Ceramide-enriched membrane domains - structure and function Biochim Biophys Acta 1788 2009 178 183
26. A.E. Cremesti, F.M. Gone, and R. Kolesnick Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett 531 2002 47 53
27. H. Grassme, J. Riethmuller, and E. Gulbins Biological aspects of ceramide-enriched membrane domains Prog Lipid Res 46 2007 161 170
28. S.N. Pinto, L.C. Silva, and A.H. Futerman Effect of ceramide structure on membrane biophysical properties: the role of acyl chain length and unsaturation Biochim Biophys Acta 2011 1808 2753 2760
29. L.C. Silva, O.B. David, and Y. Pewzner-Jung Ablation of ceramide synthase 2 strongly affects biophysical properties of membranes J Lipid Res 53 2012 430 436
30. D. Hartmann, M.S. Wegner, and R.A. Wanger The equilibrium between long and very long chain ceramides is important for the fate of the cell and can be influenced by co-expression of CerS Int J Biochem Cell Biol 45 2013 1195 1203
31. S. Grösh, S. Schiffmann, and G. Geisslinger Chain length-specific properties of ceramides Prog Lipid Res 51 2012 50 62
32. J.-W. Park, W.-J. Park, and Y. Kuperman Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes Hepatology 57 2013 525 532
33. Y.A. Hannun, and L.M. Obeid Principles of bioactive lipid signaling: lessons from sphingolipids Nat Rev Mol Cell Biol 9 2008 139 150
34. J.M. Adams, T. Pratipanawatr, and R. Berria Ceramide content is increased in skeletal muscle from obese insulin resistant humans Diabetes 53 2004 25 31
35. M. Straczkowski, and I. Kowalska The role of skeletal muscle sphingolipids in the development of insulin resistance Rev Diabet Stud 5 2008 13 24
36. L. Pickersgill, G.J. Litherland, and A.S. Greenberg Key role for ceramides in mediating insulin resistance in human muscle cells J Biol Chem 282 2007 12583 12589
37. E.S. Kilpatrick, A.S. Rigby, and S.L. Atkin Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "Double diabetes" in the Diabetes Control and Complications Trial Diabetes Care 30 2007 707 712